

Providing Value to Society



Val

Achieving a healthy and sustainable society through medical care

In Japan and other developed countries, social security spending has increased dramatically due to the rapid aging of the population and declining birthrates, so a balance between reducing medical costs and providing high-quality medical care is needed. The key to solving this issue is to extend the healthy life expectancy of people, in other words, extend the period that people can live without their daily lives being restricted by health problems.

The Group will not only improve the QOL of patients and their families by providing pharmaceuticals and medical services that meet unmet medical needs, it will also contribute to raising society's productivity by increasing the number of people who can work in good health.

Furthermore, the Group will help to prevent disease by providing vaccines that prevent infectious diseases and medical care that prevents the deterioration of the patient's condition.

We seek to achieve a sustainable society by extending the healthy life expectancy of people through the dissemination of these values.

⇒ Please see "Message from the President" on page 16 for details.

Background/Issues

Aging society

Control social security costs

Unmet medical needs

Provide value to society

Extend healthy life expectancy

Raise the QOL of patients and their families

Raise society's productivity

Prevent disease

Achieve a healthy and sustainable society

Main contribution examples

Imusera (Gilenya)

The world's first oral treatment agent for multiple sclerosis that reduces the mental and physical burden of injections. It also contributes to the improvement of patients' QOL.

Radicava (Radicut)

A treatment agent for ALS, a rare disease. It has been approved and launched as a new drug for the first time in 20 years in the U.S. and contributes to the treatment of patients.

Remicade

As the first antibody in Japan, it controls the progress of joint destruction and pain in patients caused by rheumatism, and supports their lives.

MT-2271 (Drug candidate)

VLP vaccine for seasonal influenza. Its manufacturing time can be reduced compared with conventional egg-based vaccines.

ND0612 (Drug candidate)

It was designed to reduce the burden of everyday life during treatment by combining a medical device with the treatment of Parkinson's disease.